Drugs & Aging

, Volume 30, Issue 6, pp 429–438

Efficacy and Safety of Insulin Glargine Compared to Other Interventions in Younger and Older Adults: A Pooled Analysis of Nine Open-Label, Randomized Controlled Trials in Patients with Type 2 Diabetes


    • Nova Southeastern University College of Osteopathic Medicine, Fort Lauderdale
  • Andres DiGenio
    • Sanofi US, Inc.
  • Ling Gao
    • Analystat Inc.
  • Meenakshi Patel
    • Boonshoft School of MedicineWright State University
Original Research Article

DOI: 10.1007/s40266-013-0069-9

Cite this article as:
Pandya, N., DiGenio, A., Gao, L. et al. Drugs Aging (2013) 30: 429. doi:10.1007/s40266-013-0069-9



Elderly patients with type 2 diabetes mellitus (T2DM) present therapeutic challenges related to co-morbidities, treatment adherence, and safety. This study examines the efficacy and safety of insulin glargine compared to other glucose-lowering interventions in younger and older adults.


In this pooled analysis of 24-week data from nine prospective open-label, multicenter, phase 3/4, two-arm, parallel-group, randomized controlled trials, patients with T2DM aged 18–80 years received insulin glargine (used as a basal insulin regimen) or comparators (including rosiglitazone, pioglitazone, insulin lispro, insulin lispro 75/25, NPH insulin, NPH insulin 30/70, and lifestyle/dietary measures). Endpoints included change from baseline to week 24 in: glycated hemoglobin; fasting plasma glucose; body weight; body mass index; insulin dose; incidence of nocturnal, daytime, or any hypoglycemia. Results were stratified by age (<65, ≥65, 65–74, and ≥75 years) and treatment (insulin glargine or comparator).


A total of 2,938 patients were included (2,263 aged <65 years, 675 aged ≥65 years). Similar levels of glycemic control were achieved in both younger (<65 years) and older (≥65 years) patients with T2DM. Insulin glargine was associated with better glycemic control and a reduced incidence of daytime and any hypoglycemia versus comparator interventions in both younger and older T2DM patients.


This analysis suggests that insulin glargine may represent a safe option to improve glycemic control in older patients with T2DM.

Copyright information

© Springer International Publishing Switzerland 2013